[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"social-anxiety-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:social-anxiety-disorder":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,46,71,94,117,151,190,223,249,272,308,331,362,392,424,444,467,496,530,549,573,595,619,650,681],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100475189","co2-reactivity-as-a-biomarker-of-non-response-to-exposure-based-therapy-100475189",false,"NCT05467683","CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy","Carbon Dioxide (CO2) Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy","Inclusion Criteria:\n\n* A primary DSM-5 diagnosis of panic disorder (with or without an agoraphobia diagnosis), social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, or post-traumatic stress disorder as assessed by the Structured Clinical Interview for the DSM-5 (SCID-5)\n* A score of 8 or greater on the Overall Anxiety Severity and Impairment Scale (OASIS)\n* Ages 18 to 70\n* Willingness and ability to provide informed consent and comply with the requirements of the study protocol.\n* Proficiency in English (because assessment instruments have only been validated in English)\n\nExclusion Criteria:\n\n* A lifetime history of bipolar or psychotic disorders, substance use disorders (other than nicotine) or eating disorder in the past 6 months; serious cognitive impairment.\n* Active suicidal ideation with at least some intent to act with or without specific plan (a rating of 4 for suicidal ideation on the Columbia-Suicide Severity Rating Scale) or suicidal behaviors (actual attempt, interrupted attempt, aborted or self-interrupted attempt, or preparatory acts or behavior) within the past 6 months.\n* Medical conditions contraindicating CO2 inhalation or hyperventilation challenge (e.g., cardiac arrhythmia, cardiac failure, asthma, lung fibrosis, high blood pressure, epilepsy, or stroke).\n* Pregnancy or lactation\n* Ongoing psychotherapy directed toward the primary disorder.\n* Pharmacological treatment started within 8 weeks prior to the screen (patients \"stable\" on their medication regimen will be included and their medication status will be included as a variable in the model)","ALL","18 Years","70 Years",{"count":21,"type":22},600,"ESTIMATED","INTERVENTIONAL",[25],"NA","Anxiety-, obsessive-compulsive and trauma- and stressor-related disorders reflect a significant public health problem. This study is designed to evaluate the predictive power of a novel biomarker based on a CO2 challenge, thus addressing the central question \"can this easy-to-administer assay aid clinicians in deciding whether or not to initiate exposure-based therapy?\"",[28,29,30,31,32],"Obsessive-Compulsive Disorder","Post Traumatic Stress Disorder","Generalized Anxiety Disorder","Social Anxiety Disorder","Panic Disorder","RECRUITING","2026-06-08",{"date":36,"type":37},"2026-06-10","ACTUAL",{"date":39,"type":37},"2022-11-02",{"date":41,"type":22},"2027-02-28",{"name":43,"class":44},"Jasper A. Smits","OTHER",2,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100559375","neurofeedback-enhanced-cognitive-reappraisal-training---phase-4-100559375","NCT06563310","Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4","Inclusion Criteria:\n\n* Primary diagnosis (primary source of distress and\u002For interference) of generalized anxiety disorder, social anxiety disorder, panic disorder or illness anxiety disorder based on structured interview. Comorbid phobic disorders allowed, but these cannot be the primary source of interference or distress due to the lowered chances of encountering anxiety-provoking stimuli during the study period\n* Score of 2 or more on at least 1 question from GAD\u002FCROSS-AD composite\n* Medically and physically able to consent\n* Not regularly taking any medication, prescription or non-prescription, with psychotropic effects other than:\n\n  1. Buspirone, or antidepressant (e.g., selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)) with stable dosage for past 4 weeks\n  2. The same oral hormonal contraceptive for at least 3 months\n* For females, not currently pregnant or actively trying to become pregnant\n* Ability to tolerate small, enclosed spaces without anxiety\n* No metals, implants or metallic substances within or on the body that might cause adverse effects to the subject in a strong magnetic field, or interfere with image acquisition (per protocol)\n* Size compatible with scanner gantry (per protocol)\n\nExclusion Criteria:\n\n* Current diagnosis of Obsessive Compulsive Disorder, Posttraumatic Stress Disorder, or Bipolar Disorder\n* Current substance abuse or dependence (past 6 months)\n* Active suicidality with plan or intent\n* Current psychosis\n* History of serious neurological illness or current medical condition that could compromise brain function, such as liver failure\n* History of closed head injury, e.g., loss of consciousness greater (\\>) approximately (\\~) 5 minutes, hospitalization, neurological sequela","24 Years",{"count":54,"type":22},110,[25],"This study seeks to understand emotion regulation in those with young adults with anxiety using real-time functional magnetic resonance imaging neurofeedback, a tool that allows individuals to control brain activity. The goal of this project is to understand how receiving feedback about one's own brain activity relates to emotion regulation ability. This work will help the study team understand the brain areas involved in emotion regulation and could lay the groundwork to test if psychotherapy outcomes can be enhanced using neurofeedback.\n\nThe study hypotheses include:\n\n* Participants receiving veritable-Neurofeedback (NF) will show a greater activation increases in the prefrontal cortex (PFC) compared to sham-NF\n* Participants receiving veritable-NF will show greater cognitive reappraisal (CR) ability compared to those receiving sham-NF\n* PFC activation will positively correlate with CR ability",[58,31,32,30],"Anxiety",[60],"functional magnetic resonance imaging","2026-06-03",{"date":63,"type":37},"2026-06-05",{"date":65,"type":37},"2025-01-09",{"date":67,"type":22},"2029-05",{"name":69,"class":44},"University of Michigan",1,{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":70},"100637872","safety-behavior-fading-versus-progressive-muscle-relaxation-for-appearance-concerns-100637872","NCT07589621","Safety Behavior Fading Versus Progressive Muscle Relaxation for Appearance Concerns","Safety Behavior Fading Versus Progressive Muscle Relaxation for Appearance Concerns: A Randomized Clinical Trial of Digital Interventions","Inclusion Criteria:\n\n* being between the ages of 18 and 65 years old\n* having an internet-capable smart-phone\n* scoring at or above the empirical cutoff for appearance concerns measured by the Social Appearance Anxiety Scale (i.e., 52)\n\nExclusion Criteria:\n\n* changes in psychotropic medication in the last 4 weeks\n* failing attention checks in baseline data collection","65 Years",{"count":80,"type":22},300,[25],"The current study aims to explore the efficacy of a text message based safety behavior fading intervention compared to a progressive muscle relaxation intervention for appearance concerns.",[84,85,31],"Body Dysmorphic Disorder","Eating Disorders","2026-05-29",{"date":88,"type":37},"2026-06-02",{"date":86,"type":37},{"date":91,"type":22},"2026-12",{"name":93,"class":44},"Florida State University",{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":115,"locationsCount":70},"100413448","computer---based-treatment-for-social-anxiety-disorder-100413448","NCT04663724","Computer - Based Treatment for Social Anxiety Disorder","Computer-Based Treatment for Social Anxiety Disorder, A Randomized Controlled Trial","Inclusion Criteria:\n\n* Males and females between the ages of 18 to 60\n* Current primary diagnosis of SAD\n* Score of at least 50 on the Liebowitz Social Anxiety Scale (self-rated version)\n* Fluent in English\n* Willing and able to give informed written consent\n* Ability to participate responsibly in the protocol\n* Normal or corrected-to-normal vision\n\nExclusion Criteria:\n\n* Present or past psychotic episode, psychotic disorder, schizophrenia, schizoaffective disorder, or bipolar disorder\n* Current severe depression\n* Suicidal ideation or behavior\n* Current diagnosis of post-traumatic stress disorder, obsessive-compulsive disorder, bipolar disorder, manic episode or tic disorder\n* Current or past organic mental disorder, seizure disorder, epilepsy or brain injury\n* Current unstable or untreated medical illness\n* Severe alcohol use disorder, severe cannabis use disorder, and any severity of other substance use disorder (except nicotine use disorders)\n* Use of psychiatric medication in the past month other than a stable dose of selective serotonin reuptake inhibitors (SSRIs) for at least 3 months\n* Any concurrent cognitive behavioral therapy or other psychotherapy that was initiated in the past 3 months\n* Pregnancy, or plans to become pregnant during the period of the study (will be assessed by urine)\n* Contraindication to MRI scanning (Paramagnetic metallic implants or devices contraindicating magnetic resonance imaging or any other non-removable paramagnetic metal in the body)\n\n  1. pacemaker\n  2. paramagnetic metallic prosthesis\n  3. surgical clips\n  4. shrapnel\n  5. necessity for constant medicinal patch\n  6. some tattoos\n* Inability to tolerate MRI scanning procedures (i.e., severe obesity, claustrophobia)","60 Years",{"count":103,"type":22},80,[25],"The present study is a controlled trial that seeks to examine the feasibility, acceptability, mechanism, and efficacy of a recently developed computer-based therapy in individuals with social anxiety disorder (SAD)",[31],[108],"Attention","2026-05-28",{"date":111,"type":37},"2026-06-01",{"date":113,"type":37},"2021-02-15",{"date":41,"type":22},{"name":116,"class":44},"New York State Psychiatric Institute",{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":123,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":127,"briefSummary":128,"conditions":129,"keywords":130,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":70},"100491752","neural-markers-of-treatment-mechanisms-and-prediction-of-treatment-outcomes-in-social-anxiety-100491752","NCT05683223","Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety","Inclusion criteria for all participants:\n\n(1) Any gender or race between 18-50 years old.\n\nAdditional inclusion criteria for healthy controls:\n\n(1) Liebowitz Social Anxiety Scale (LSAS; Mennin et al., 2002) score \\\u003C= 30, does not currently meet criteria for an Axis I psychiatric condition, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5; American Psychiatric Association, 2013).\n\nAdditional inclusion criteria for the social anxiety disorder (SAD) group:\n\n1. Outpatients with a primary psychiatric complaint (designated by the patient as the most important source of current distress) of social anxiety with social interaction fear as defined by an Liebowitz Social Anxiety Scale (LSAS) score \\>= 60.\n2. Overall clinical severity of at least mild as defined by Clinical Global Impressions Scale (CGI-S; Zaider et al., 2003) of at least 3.\n3. Medical history interview and laboratory findings without clinically significant abnormalities.\n4. Willingness and ability to participate in the informed consent process and comply with the requirements of the study protocol.\n\nExclusion criteria:\n\n1. A lifetime history of bipolar disorder, schizophrenia, psychosis, delusional disorders or obsessive-compulsive disorder; an eating disorder in the past 6 months; organic brain syndrome, intellectual disability, or other cognitive dysfunction that could interfere with capacity to engage in therapy; a history of substance or alcohol abuse or dependence (other than nicotine) in the last 6 months or otherwise unable to commit to refraining from alcohol, marijuana, and stimulant use during the acute period of study participation.\n2. . Patients with significant suicidal ideation Montgomery-Åsberg Depression Rating Scale (10 items, self-report) or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.\n3. Patients can be taking a concurrent psychotropic medication (e.g., antidepressants, anxiolytics, beta blockers, sertraline), but the dose must be stabilized for at least 2 weeks prior to initiation of randomized treatment.\n4. Significant personality dysfunction likely to interfere with study participation.\n5. Serious medical illness, associated treatment, or other instability for which hospitalization may be likely within the next year, or which may alter fMRI or EEG measurements. Participants with a history of serious medical illness or treatments that may alter fMRI measurements may enroll in the study 12 months after the condition has been remitted and ending treatment.\n6. Patients with a current or past history of seizures.\n7. Pregnant women, lactating women, and women of childbearing potential who may become pregnant.\n8. Any concurrent psychotherapy initiated within 3 months of baseline, or ongoing psychotherapy of any duration directed specifically toward treatment of the social anxiety is excluded. Individuals with prior CBT experience or treatments that included cognitive and behavioral skills and exposure procedures (e.g., assertiveness and social skills trainings) will be excluded. General supportive or insight-oriented therapy initiated \\> 3 months prior is acceptable.\n9. Prior non-response to adequately-delivered exposure (i.e., as defined by the patient's report of receiving specific and regular exposure assignments as part of a previous treatment).\n10. Patients with a history of head trauma causing loss of consciousness, seizure or ongoing cognitive impairment.\n11. Contraindications for MRI including metal implants, surgical clips, probability of metal fragments, braces, or claustrophobia.",true,"50 Years",{"count":126,"type":22},240,[25],"The purpose of this clinical trial is to answer the question: can the investigators predict which adults with social anxiety disorder (SAD) will successfully respond to treatment? To answer this question, the investigators plan to recruit 190 adult participants who experience extreme forms of social anxiety to undergo brain imaging before and after 12 weeks of group cognitive behavioral therapy (CBT). Adults in the SAD group who do not respond enough to group CBT may be offered the opportunity to complete an additional 12 weeks of individual CBT while receiving SSRI medication (sertraline, see below) for SAD.\n\nData collected from participants who experience anxiety will be compared to a group of 50 participants with little or no social anxiety, who will serve as a comparison group.",[31],[131,132,133,134,135,136,137,138,139,140,141],"social anxiety disorder","sertraline","exposure therapy","social cost","MRI","EEG","structural connectivity","functional connectivity","cognitive control system","positive valence system","negative valence system","2026-05-14",{"date":144,"type":37},"2026-05-18",{"date":146,"type":37},"2023-05-26",{"date":148,"type":22},"2027-06-30",{"name":150,"class":44},"Boston University Charles River Campus",{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":17,"minAge":159,"maxAge":18,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":163,"conditions":164,"keywords":176,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":70},"100587910","implementing-team-based-treatment-for-pediatric-anxiety-in-community-mental-health-settings-100587910","NCT06934525","Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings","Testing Delivery of Modalities in Community Health Settings: Developing Pathways to Health Equity","IMPACT-RI","Inclusion Criteria:\n\n* Age 5-18 inclusive\n* Primary or co-primary DSM-V diagnosis of anxiety or OCD\n* Symptom duration of at least 3 months\n* Outpatient care needed\n* Presence of a stable parent, or guardian, who can participate in treatment\n\nExclusion Criteria:\n\n* Other primary or co-primary psychiatric disorder which requires initiation of other active current treatment\n* Acute suicidality\n* Concurrent psychotherapy\n* Chronic medical illness that would preclude their active participation in treatment\n* Treatment with psychotropic medication that is not stable","5 Years",{"count":161,"type":22},501,[25],"The purpose of this study is to test how the delivery of Cognitive Behavioral Therapy (CBT) for pediatric anxiety and OCD via different methods might increase its availability and effectiveness. CBT involves teaching the patient skills to enable them to gradually come into contact with feared situations. This process of gradually approaching feared situations is called exposure. Although CBT with exposure has the best evidence for treating anxiety disorders, not all children have equal access or respond the same way to CBT. As part of this study, patients will receive weekly CBT treatment sessions involving a combination of weekly visits with an exposure coach and one visit a month with a licensed provider (e.g., psychologist, social worker). This treatment will be delivered using one of three methods: 1) in-person (face-to-face sessions, occurring in the office and the home\u002Fcommunity), or 2) telehealth (entirely remote sessions via web-based video conference), or 3) flexible (individualized mix of in-person and\u002For telehealth sessions). Eligible participants will be randomly assigned to one of these three methods. Results of this study will help determine which treatment method works best for whom.\n\nTreatment as described above will occur as part of care at partnering community care sites in Rhode Island. Providers from the following partnering community care sites will make up patient treatment teams: Blackstone Valley Community Health Care, Family Services of Rhode Island, Gateway Healthcare, Newport Mental Health, and Thrive Behavioral Health.\n\nThe research study is being conducted by the Pediatric Anxiety Research Center at Brown University Health. The research team will conduct the study assessments that patients will be asked to participate in as study participants. Patients will be asked to complete assessments prior to starting treatment, at two time points during treatment, at the end of treatment, and at two timepoints 3 and 6 months following the end of treatment. Participants will be compensated for their time completing research assessments.",[165,166,167,58,168,169,170,171,30,172,173,174,31,32,175],"Obsessive Compulsive Disorder (OCD)","Pediatric Anxiety Disorders","Anxiety Disorder","OCD","Phobia","Agoraphobia","Generalized Anxiety","Selective Mutism","Separation Anxiety","Social Anxiety","Pediatric Disorders",[133,177,178,179,180,181],"cognitive behavioral therapy","anxiety treatment","exposure and response prevention therapy","ERP","pediatric anxiety treatment","2026-05-13",{"date":142,"type":37},{"date":185,"type":37},"2025-11-01",{"date":187,"type":22},"2029-08-01",{"name":189,"class":44},"Bradley Hospital",{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":199,"briefSummary":200,"conditions":201,"keywords":204,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":70},"100423436","a-transdiagnostic-self-guided-internet-intervention-velibra-for-waitlist-patients-with-anxiety-disorders-100423436","NCT04793828","A Transdiagnostic, Self-guided Internet Intervention (\"Velibra\") for Waitlist Patients With Anxiety Disorders","The Effect of a Transdiagnostic, Self-guided Internet Intervention (\"Velibra\") for Waitlist Patients With Anxiety Disorders","Inclusion Criteria:\n\n* Diagnosis of panic disorder with or without agoraphobia, social anxiety disorder, or generalized anxiety disorder\n* Knowledge of German that is sufficient for engaging with the treatment and responding to the questionnaires\n* Written informed consent\n* Internet access\n\nExclusion Criteria:\n\n* Diagnoses of severe mental comorbidities (e.g., schizophrenia, severe major depression, borderline personality disorder)\n* Acute suicidality\n* Started or changed anxiolytic pharmacotherapy recently (currently or in the past four weeks)",{"count":198,"type":22},30,[25],"The project's aim is to investigate the effect of a transdiagnostic, self-guided, internet-based cognitive behavioral therapy program in waitlist patients with anxiety disorders.",[202,203,30,31],"Panic Disorder With Agoraphobia","Panic Disorder Without Agoraphobia",[177,205,206,207,208,131,209,210,211,212,213],"internet intervention","administrative-supported","anxiety","panic disorder","generalized anxiety disorder","computerized CBT","anxiety disorders","velibra","psychotherapy","2026-05-06",{"date":216,"type":37},"2026-05-07",{"date":218,"type":37},"2020-07-04",{"date":220,"type":22},"2027-12-31",{"name":222,"class":44},"Charite University, Berlin, Germany",{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":17,"minAge":230,"maxAge":101,"enrollmentInfo":231,"targetDuration":4,"studyType":232,"phases":4,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":70},"100618288","an-examination-of-the-performance-of-qbmobile-in-differential-diagnosis-associated-with-adhd-symptoms-100618288","NCT07329673","An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms","An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms.","Inclusion Criteria:\n\n* Provide written informed consent (including parent\u002Flegal guardians consent when this is required for individuals under 18 years old and assent as is required based on the age of participant) for QbMobile;\n* Aged \\> 6 years and \\\u003C 60 years old;\n* Referred for an initial assessment for ASD, MDD, Bipolar Disorder or Anxiety Disorder (Separation Anxiety Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD)) or has a prior diagnosis of one of the included disorders but is not currently receiving treatment;\n* Meets DSM-5 or ICD-11 criteria for a primary diagnosis of ASD, MDD, Bipolar Disorder or Anxiety Disorder per sites standard clinical procedures;\n* Have adequate sensory and physical ability to complete QbMobile;\n* Possess or have access to an iPhone model that supports QbMobile.\n\nExclusion Criteria:\n\n* Intellectual disability designated by IQ\\\u003C70;\n* Has a DSM-5 or ICD-11 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder due to another medical condition, PTSD, antisocial personality disorder, or borderline personality disorder;\n* Has a primary diagnosis of ADHD (combined, inattentive, or hyperactivity\u002Fimpulsive presentation);\n* Has a concurrent medical diagnosis that could significantly affect test performance such as brain injuries, Parkinson's disease, current epilepsy or active seizures, amyotrophic lateral sclerosis (ALS), multiple sclerosis, dementias (e.g. vascular dementia, Alzheimer disease, etc);\n* Has other conditions that could affect test performance (migraine or other types of severe headache, chronic or acute pain);\n* Use of prescription medications (e.g., anxiolytics, sedative medications) taken on the day before completing QbMobile that could significantly affect performance;\n* Substance use (e.g., alcohol, drugs) that may affect performance on the day of the tests.","6 Years",{"count":80,"type":22},"OBSERVATIONAL","The purpose of this study is to evaluate QbMobile's ability to collect objective data to identify specific symptom profiles in differential diagnoses (ASD, MDD, Bipolar Disorder and Anxiety Disorder) that are common with ADHD.",[235,236,237,238,31,239],"Bi-Polar Disorder","Autism Spectrum Disorder (ASD)","Major Depression Disorders","Separation Anxiety Disorder","Generalized Anxiety Disorder (GAD)","2026-05-04",{"date":214,"type":37},{"date":243,"type":37},"2026-01-01",{"date":245,"type":22},"2026-11",{"name":247,"class":248},"Qbtech AB","INDUSTRY",{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":256,"targetDuration":4,"studyType":23,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":70},"100595112","mindful-self-compassion-for-anxiety-and-depression-impact-of-delivery-method-100595112","NCT07028216","Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method","Mindful Self-Compassion for Anxiety and Depression: A Randomized Comparison of In-Person Versus Videoconference Delivery","Inclusion Criteria:\n\n* Must have a primary anxiety disorder (social anxiety disorder, generalized anxiety disorder, panic disorder, or agoraphobia) or major depressive disorder, current\n* Must score low on self-compassion, as measured by the self-compassion scale\n* Must understand study procedure and willing to participate in all testing visits, and treatment as assigned\n* Must be able to give informed consent to the study procedures\n\nExclusion Criteria:\n\n* Comorbid psychiatric disorder other than anxiety or depression, such as psychotic disorder, obsessive compulsive disorder, eating disorders (i.e., anorexia and bulimia), bipolar disorder; developmental or organic mental disorders; and current (past 6 months) substance use disorders and current post-traumatic stress disorder as assessed by clinician at screening visit\n* A serious medical condition that may result in surgery or hospitalization.\n* A history of head trauma causing prolonged loss of consciousness, or ongoing cognitive impairment\n* Inability to understand study procedures or informed consent process, or significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview).\n* Subjects who will be non-compliant with the study procedures. This may include planned travel out of town.\n* Subjects taking some psychiatric medication such as barbiturates or antipsychotics. Sleep medications and some anti-depressants will be allowed, if the subject has been taken at stable dose 8 weeks prior to baseline and the patient plans to continue at the same dose through the trial.\n* Concurrent psychotherapy initiated within 1 month of screen interview, or ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety (such as Cognitive Behavioral Therapy).\n* Individuals who have completed a course of MSC or an equivalent meditation training in the last year.\n* Individuals reporting significant active suicidal ideation or suicidal behaviors within the past year.\n* Individuals with a medical condition (i.e., epilepsy) that may be exacerbated by study treatment, as determined by a study physician or nurse practitioner based on history, physical, and\u002For labs.\n* Adults unable to consent\n* Pregnant women\n* Prisoners",{"count":103,"type":22},[25],"The study will compare the delivery of an 8-week Mindful Self-Compassion training, in-person against video-conference, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or major depressive disorder or dysthymia.",[260,30,31,32,170,261,262],"Anxiety Disorders","Major Depressive Disorder","Persistent Depressive Disorder (Dysthymia)","2026-05-03",{"date":265,"type":37},"2026-05-05",{"date":267,"type":37},"2025-06-01",{"date":269,"type":22},"2027-08-31",{"name":271,"class":44},"Georgetown University",{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":280,"enrollmentInfo":281,"targetDuration":4,"studyType":23,"phases":283,"briefSummary":284,"conditions":285,"keywords":291,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":70},"100531301","targeting-social-function-in-anxiety-and-eating-disorders-100531301","NCT06198023","Targeting Social Function in Anxiety and Eating Disorders","Targeting Social Function to Improve Outcomes in Anxiety and Eating Disorders","SF","Inclusion Criteria:\n\n* In the past 12 months, has met DSM-5 criteria met for an eating disorder (Anorexia Nervosa, Atypical Anorexia Nervosa, Bulimia Nervosa, Avoidant-Restrictive Food Intake Disorder, or Other Specified Feeding or Eating Disorder) and\u002For an anxiety disorder (Generalized Anxiety Disorder, Social Anxiety Disorder)\n* Between the ages of 18-30\n\nExclusion Criteria:\n\n* Current inpatient or residential treatment\n* Medical instability or safety\u002Fsuicide risk as determined by the PI","30 Years",{"count":282,"type":22},60,[25],"Social processing and cognition are often altered in patients with eating disorders. The goal of this clinical trial is to assess two different social therapeutic interventions -- one educational, one interactive -- for their effectiveness in improving clinical outcomes in patients with eating disorders. Patients in both interventions will receive education about social function in eating disorders, but those in the interactive treatment group will complete an additional collaborative art task.\n\nParticipants will:\n\n* attend a baseline study visit to complete clinical interviews, cognitive testing, and behavioral tasks\n* complete a pre-intervention assessment with questionnaires\n* attend eight sessions of their assigned treatment group over the course of 12 weeks\n* complete three virtual follow-up assessments 4, 8, and 12 months from their baseline\n* attend a final study visit to repeat some clinical interviews, cognitive testing, and behavioral tasks\n\nResearchers will compare changes in eating disorder, mood, and anxiety symptoms as well as test results from baseline and final study visits for each group to see if\n\n* patients can be treated effectively with education alone or if an interactive group component produces additional benefits\n* cognitive and behavioral task performance are associated with recovery or illness state.",[85,286,287,288,289,290,31,239],"Anorexia Nervosa","Bulimia Nervosa","Atypical Anorexia Nervosa","Purging (Eating Disorders)","Other Specified Feeding or Eating Disorder",[292,293,294,295,296,297,298,299],"social function","social cognition","social processing","psychoeducation","group therapy","group intervention","art therapy","social anxiety","2026-04-28",{"date":265,"type":37},{"date":303,"type":37},"2024-02-28",{"date":305,"type":22},"2028-09",{"name":307,"class":44},"University of Texas Southwestern Medical Center",{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":17,"minAge":315,"maxAge":124,"enrollmentInfo":316,"targetDuration":4,"studyType":23,"phases":318,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":70},"100537152","using-tms-to-understand-neural-processes-of-social-motivation-100537152","NCT06274112","Using TMS to Understand Neural Processes of Social Motivation","Personalized Neuromodulation Targeting Dysregulated Motivational Responses Underlying Social Avoidance Behavior","Inclusion Criteria:\n\n* A diagnosis of Major Depressive Disorder OR a diagnosis of Social Anxiety Disorder (assessed\u002Fconfirmed at screening visit).\n* Scoring above clinical threshold on a measure of social avoidant behavior (assessed\u002Fconfirmed at phone screen).\n\nExclusion Criteria:\n\n* Unstable psychotropic medication regimen (i.e., changes in psychotropic medication or dosage in past 3 months).\n* Current or lifetime diagnosis of Bipolar Disorder.\n* A diagnosis of substance use disorder within past 12 months.\n* A diagnosis of psychotic-spectrum disorder such as Schizophrenia.\n* Pregnancy or probable pregnancy.\n* Medical illness or medical treatment that would preclude or inhibit study participation.\n* Neurological disorder associated with brain damage.\n* History of seizures or head trauma with loss of consciousness \\> 5 minutes.\n* Family history of epilepsy or personal epilepsy\u002Fseizures\n* Ferromagnetic implants or ferrmagnetic objects within body (e.g., pacemaker).","25 Years",{"count":317,"type":22},40,[25],"The purpose of this study is to use transcranial magnetic stimulation (TMS) to better understand the neural circuits associated with social motivation.\n\nParticipant includes four study visits each that range from 1.5 - 3.0 hours in duration over approximately a one month period. The first study visit involves answering survey questions, a clinical interview, and computer tasks. The second study visit involves a magnetic resonance imaging (MRI) scan, computer tasks, and a brief TMS protocol. The second and third study visits involve a full session of TMS followed by an MRI scan and computer tasks.\n\nAdults in the Auburn\u002FOpelika area and surrounding areas who avoid social situations, experience symptoms of depression or social anxiety, and are between 25 years old and 50 years old are eligible to participate.",[321,261,31],"Social Avoidant Behavior","2026-03-01",{"date":324,"type":37},"2026-03-03",{"date":326,"type":37},"2025-09-30",{"date":328,"type":22},"2029-07-31",{"name":330,"class":44},"Auburn University",{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":338,"maxAge":339,"enrollmentInfo":340,"targetDuration":4,"studyType":23,"phases":342,"briefSummary":343,"conditions":344,"keywords":346,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":70},"100588517","stepped-versus-stratified-care-for-anxiety-disorders-in-youth-100588517","NCT06942429","Stepped Versus Stratified Care for Anxiety Disorders in Youth","Stepped Versus Stratified Care for Anxiety Disorders in Youth: A Pragmatic Non-Inferiority Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 8.0 to 17.5 years. Confirmed by the child and\u002For caregiver.\n2. Principal DSM-5-TR anxiety disorder of social anxiety disorder, generalized anxiety disorder, panic disorder, separation anxiety disorder, specific phobia, or agoraphobia. Confirmed by the structured diagnostic interview (DIAMOND-KID). \"Principal\" indicates that the anxiety disorder is judged by the clinician to be in most urgent need of treatment (among potential co-occurring disorders).\n3. Available caregiver who can support the child in treatment. Confirmed by the caregiver.\n4. Child and at least one caregiver can read, write, and communicate in Swedish. Confirmed by the child and\u002For caregiver.\n5. Child (≥13 years) and caregiver have access to a Swedish electronic identification (BankID or Freja eID).\n6. Access to the internet. Confirmed by the child and\u002For caregiver.\n7. Ability to attend in-person CBT sessions at the clinic. Confirmed by the child and\u002For caregiver.\n\nExclusion Criteria:\n\n1. Principal DSM-5-TR anxiety disorder of specific phobia concerning the domain of blood-injection-injury (due to the ICBT program not including relevant information on applied-tension techniques to avoid fainting during exposure exercises). Confirmed by a specific phobia of this sort being classified as the most functionally impairing anxiety disorder during the structured diagnostic interview (DIAMOND-KID).\n2. Ongoing psychological treatment for an anxiety disorder. Confirmed by the child and\u002For caregiver.\n3. Social\u002Ffamilial\u002Feducational difficulties in more immediate need of management than an anxiety disorder. Confirmed by the assessor through information from the child and\u002For caregiver and\u002For other available sources.\n4. Immediate risk to self or others that require urgent attention, such as suicidality. Confirmed by the assessor through information from the child and\u002For caregiver and other available sources.\n5. The potential participant has a relative (e.g., sibling, cousin) included in the study. Confirmed by the assessor through information from the caregiver and other available sources.","8 Years","17 Years",{"count":341,"type":22},556,[25],"The goal of this clinical trial is to compare stepped care to stratified care as overall healthcare models for children and adolescents aged 8-17 with anxiety disorders. It addresses one main question:\n\n• Is stepped care non-inferior to stratified care in supporting participants to achieve a treatment response?\n\nResearchers will compare two care models:\n\n* Stepped care, where all participants begin with 14 weeks of internet-delivered cognitive behavioral therapy (ICBT) and receive an additional 14 weeks of personalized in-person CBT if needed.\n* Stratified care, where participants are assigned to either 14 weeks of ICBT or 14 weeks of in-person CBT based on clinical complexity, and may also receive additional 14 weeks of in-person CBT if necessary.\n\nParticipants will:\n\n* Be randomly assigned to one of the two care models.\n* Complete a wide range of assessments at baseline, during treatment, and at 4, 8, 12, and 24 months, with the 8-month point as the primary endpoint.\n* Receive either ICBT, in-person CBT, or both, depending on their care model and response to treatment.\n* Participate in ancillary studies involving DNA sampling, cognitive testing, and national registry linkages to help predict treatment response and long-term outcomes.",[31,238,345,32,30,170],"Specific Phobia",[211,347,348,177,349,350,351,352],"children","adolescents","non-inferiority","care models","stepped care","stratified care","2026-02-24",{"date":355,"type":37},"2026-02-27",{"date":357,"type":37},"2025-06-19",{"date":359,"type":22},"2031-03-05",{"name":361,"class":44},"Region Skane",{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":17,"minAge":338,"maxAge":339,"enrollmentInfo":369,"targetDuration":4,"studyType":23,"phases":371,"briefSummary":372,"conditions":373,"keywords":375,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":70},"100566921","internet-delivered-cognitive-behavioral-intervention-for-youths-with-anxiety-disorders-100566921","NCT06661460","Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders","Development and Preliminary Evaluation of a New Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders","Inclusion Criteria:\n\n1\\) 8 to \\\u003C18 years of age.\n\n* Confirmed by the child\u002Fcaregiver and subsequently by the medical record system. 2) A principal DSM-5-TR anxiety disorder of specific phobia, separation anxiety disorder, social anxiety disorder, generalized anxiety disorder, panic disorder or agoraphobia.\n* Confirmed by the Diagnostic Interview for Anxiety, Mood, and OCD and related Neuropsychiatric Disorders - Child and Adolescent Version (DIAMOND-KID).\n\n  3\\) Child and caregiver able to read, write and communicate in Swedish.\n* Confirmed by the child\u002Fcaregiver. 4) An available caregiver who can support the child in treatment.\n* Confirmed by the caregiver. 5) Access to a smartphone, tablet, or laptop\u002Fdesktop device, and the internet.\n* Confirmed by the child\u002Fcaregiver.\n\nExclusion Criteria:\n\n1\\) Principal DSM-5-TR anxiety disorder of specific phobia concerning the domain of blood-injection-injury (due to the ICBT program not including relevant information on applied-tension techniques to avoid fainting during exposure exercises).\n\n* Confirmed by a blood-injection-injury phobia being classified as the principal anxiety disorder as assessed by the DIAMOND-KID.\n\n  2\\) Established or suspected intellectual disability.\n* Confirmed by the caregiver (through previous diagnosis) and\u002For by attending a special needs school for learning difficulties.\n\n  3\\) Another mental disorder in more immediate need of management than an anxiety disorder (e.g., schizophrenia spectrum and other psychotic disorders, bipolar disorder, anorexia nervosa, substance use disorders).\n* According to the DIAMOND-KID and\u002For other available sources. 4) Social\u002Ffamilial\u002Feducational difficulties in more immediate need of management than an anxiety disorder.\n* Confirmed by the assessor through information from the child\u002Fcaregiver and\u002For other available sources.\n\n  5\\) Immediate risk to self or others that require urgent attention, such as acute suicidality.\n* Confirmed by the assessor through information from the child\u002Fcaregiver and other available sources.\n\n  6\\) Previous CBT for an anxiety disorder, defined as five or more sessions with a certified CBT therapist within the 12 months prior to assessment.\n* Confirmed by the child\u002Fcaregiver or the medical record system. 7) Ongoing psychological treatment for an anxiety disorder.\n* Confirmed by the child\u002Fcaregiver or the medical record system. 8) Initiation or adjustment of any psychotropic medication for anxiety (i.e., selective serotonin reuptake inhibitors, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitor or antipsychotics) within 8 weeks prior to assessment.\n* Confirmed by the child\u002Fcaregiver or the medical record system. 9) Participation in user involvement sessions in the present study.\n* Confirmed by the researcher.",{"count":370,"type":22},48,[25],"The goal of this study is to develop a new internet-delivered cognitive behavioral therapy (ICBT) intervention for youths with anxiety disorders based on the best current knowledge about effective cognitive behavioral therapy for the target group, refine the intervention in collaboration with patient and public representatives, and conduct a preliminary evaluation of the treatment effects in an open clinical trial.\n\nThe primary objective of the study is:\n\n1\\. To evaluate the preliminary efficacy of a newly developed ICBT intervention for children and adolescents with anxiety disorders in reducing anxiety severity, as measured by the Pediatric Anxiety Rating Scale (PARS).\n\nSecondary objectives of the study are:\n\n1. To examine the preliminary efficacy (PARS) of the ICBT intervention at 3 months post-treatment.\n2. To examine how youths with anxiety disorders, their caregivers, therapists, and healthcare leadership experience the ICBT intervention.\n3. To examine factors (e.g., age, type of anxiety disorder, presence of depressive symptoms, experiences of ICBT) that predict treatment outcome.\n4. To examine how the ICBT intervention can be improved (e.g., treatment content and technical delivery) for future use.\n\nParticipants will:\n\n* Undergo ICBT treatment for anxiety disorders during 12 weeks\n* Complete questionnaires at multiple time points throughout the study\n* Participate in follow-ups post-treatment and 3 months post-treatment\n* A selection of participants will also be invited to focus group interviews with the aim to generate ideas on how the intervention may be improved for future use",[374,345,31,238,30,32,170],"ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)",[376,377,378,379,380,381,382],"Anxiety disorders","Children","Adolescents","Cognitive Behavioral Therapy","Remote delivery","Internet","Internet-delivered cognitive behavioral therapy","2026-02-19",{"date":385,"type":37},"2026-02-20",{"date":387,"type":37},"2025-12-12",{"date":389,"type":22},"2027-06-01",{"name":391,"class":44},"Lund University",{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":123,"sex":17,"minAge":18,"maxAge":400,"enrollmentInfo":401,"targetDuration":4,"studyType":23,"phases":403,"briefSummary":404,"conditions":405,"keywords":406,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":70},"100568213","individual-factors-of-cbt-underlying-success-100568213","NCT06678295","Individual Factors of CBT Underlying Success","Contributions of Self-Focused Attention to Early Warning Indicators of Cognitive Behavioral Therapy Non-Response","I-FOCUS","Inclusion Criteria:\n\nClinical sample (N=110):\n\n1. Men and women, age 18-45\n2. Treatment-seeking individuals who meet criteria for a primary DSM-5 diagnosis of primary social anxiety disorder (SAD) or body dysmorphic disorder (BDD) based on the SCID-5-RV\n3. Fluent in English and willing to provide informed consent.\n\nControl sample (N=50):\n\n1. Men and women, age 18-45\n2. No current or lifetime history of psychiatric disorders, as assessed using the SCID-5-RV\n3. Meet criteria for low levels of anxiety (GAD-7 score of \\\u003C8) and depression (PHQ-9 score \\\u003C10)\n4. Fluent in English and willing to provide informed consent\n\nExclusion Criteria:\n\nAll groups:\n\n1. Score \\\u003C 80 based on WRAT5 Word Reading Subtest\n2. fMRI contraindications (e.g., electronic medical devices such as pacemakers, implanted defibrillators, etc.; metal implants not approved for MRI; pregnancy; claustrophobia)\n\n2\\. Active suicidal or homicidal ideation, or any features requiring a higher level of care 3. Lifetime history of manic or hypomanic episode, psychotic symptoms, traumatic brain injury, neurological disorder, pervasive developmental disorder, or attention deficit-hyperactivity disorder; active alcohol or substance use disorder in the past 6 months 4. Current use of psychotropic medications, except antidepressants taken at a stable dose for 3 months prior to study baseline 5. Previous CBT non-responder or current CBT","45 Years",{"count":402,"type":22},160,[25],"The purpose of this study is to understand why some individuals respond fully to cognitive behavioral therapy and others do not, based on multiple sources of data such as neural, neurocognitive, clinical, and self-report data.",[31,84],[84,31,407,408,409,410,411,412,413,414],"Social Phobia","Self focused attention","fMRI","CBT","Cognitive Behavior Therapy","BDD","SAD","Neuroimaging","2026-02-13",{"date":417,"type":37},"2026-02-17",{"date":419,"type":37},"2024-10-15",{"date":421,"type":22},"2028-09-30",{"name":423,"class":44},"University of Washington",{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":123,"sex":17,"minAge":18,"maxAge":431,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":433,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":70},"100461742","cvc-sad-clinician-vs-coachself-help-versions-in-a-rct-100461742","NCT05292612","CvC-SAD (Clinician vs Coach)Self-help Versions in a RCT","Chinese Internet-delivered Cognitive Therapy for Social Anxiety Disorder in Hong Kong: A Randomised Controlled Noninferiority Trial to Compare Clinician Versus Coach Guidance","Inclusion\n\n* Meets DSM-5 criteria for SAD (SAD must be generalised, not the 'performance only' subtype)\n* Considers SAD their main problem\n* Age 18 or over (no upper age limit)\n* No current psychotropic mediation, or on a stable dose for at least two months without improvement, and willing to remain at this dose throughout trial\n* Participant agrees not to start any other forms of treatment during the trial\n* Chinese resident of Hong Kong\n* Proficient in written traditional Chinese and spoken Cantonese\n* Internet access from home\n\nExclusion\n\n* current or past psychosis, bipolar disorder, or borderline personality disorder\n* active suicidality\n* 'Moderate' or 'Severe' Alcohol Use Disorder or Substance Use Disorder (based on DSM-5)\n* No current or previous CBT for SAD (defined as at least 5 sessions, and including an exposure component), including internet-CBT studies\n* Not another current emotional problem that is the participant's main concern (Participant must not be largely absorbed in another emotional problem, for which it would be unethical not to address as a priority)","100 Years",{"count":54,"type":22},[25],"Background:\n\nSocial Anxiety Disorder (SAD) is a common mental problem, where people experience severe and disabling anxiety about social situations and interactions. It is highly prevalent world-wide and in Hong Kong, causing significant suffering\u002Fdistress. While evidence-based interventions exist, e.g., cognitive behavioural therapy (CBT), there will be not enough trained therapists to meet the treatment demand so that the majority of the SAD patients receive no treatment. Internet-based therapies may offer a solution, given that they deliver treatment more cost-efficiently by requiring lesser therapist time so that more patients can be treated with the same therapist resources. One UK internet-based CBT protocol for SAD, iCBT(C\\&W), shows high efficacy and efficiency in initial UK and Hong Kong trials with Englishspeaking patients.\n\nObjectives:\n\n1. To develop and confirm the efficacy of a Chinese-language version of iCBT(C\\&W), administered by clinical psychologists in standard therapist-guided format.\n2. To develop an even more cost-efficient new self-help format with some minimal 'coaching' performed by trained psychology bachelor-level graduates - its efficacy expected as 'noninferior' to that of the therapist-guided format.\n\nOverall design:\n\nThree-arm parallel group randomised controlled noninferiority trial: Standard therapist-guided iCT-SAD vs. Guided self-help iCT-SAD vs. Waitlist\n\nMethod:\n\nThe iCBT(C\\&W) protocol will be translated into Chinese. Approximately 110 Chinese adults with SAD will be recruited in Hong Kong and randomised into one of two treatment conditions, therapist-guided versus self-help. The treatment lasts 14 weeks. The primary outcome measure will be Liebowitz Social Anxiety Scale (self-report version).",[31],{"date":437,"type":37},"2026-02-18",{"date":439,"type":37},"2023-05-01",{"date":441,"type":22},"2026-12-31",{"name":443,"class":44},"Chinese University of Hong Kong",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":451,"enrollmentInfo":452,"targetDuration":4,"studyType":23,"phases":454,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":70},"100505207","comparing-tbt-to-disorder-specific-psychotherapy-in-veterans-with-social-anxiety-disorder-100505207","NCT05858346","Comparing TBT to Disorder-Specific Psychotherapy in Veterans With Social Anxiety Disorder","A Randomized Clinical Trial Comparing Transdiagnostic Behavior Therapy to Disorder-Specific Psychotherapy in the Recovery of Veterans With Social Anxiety Disorder and Comorbid PTSD Symptomatology","Inclusion Criteria:\n\n* Participants must be Veterans and registered at Ralph H. Johnson Veterans Affairs Health Care System\n* Participants must be clearly competent to provide informed consent for research participation\n* Participants must meet DSM-5 criteria for social anxiety disorder\n* Participants must have clinically significant symptoms of comorbid posttraumatic stress\n\nExclusion Criteria:\n\n* recent history (\\\u003C 2 months) of psychiatric hospitalization or a suicide attempt as documented in their medical record,\n* acute, severe illness or medical condition that likely will interfere with study procedures as documented in their medical record\n* recent start of new psychiatric medication(s) (\\\u003C 4 weeks),\n* primary diagnosis of a condition associated with psychotic symptoms, personality disorder, substance use disorder, or bipolar disorder.","80 Years",{"count":453,"type":22},264,[25],"Cognitive behavioral therapy (CBT) is a brief, efficient, and effective treatment for individuals with depressive\u002Fanxiety disorders. However, CBT is largely underutilized within the Department of Veterans Affairs due to the cost and burden of trainings necessary to deliver all of the related disorder-specific treatments (DSTs). Transdiagnostic Behavior Therapy (TBT), in contrast, is specifically designed to address numerous distinct disorders within a single protocol in Veterans with depressive\u002Fanxiety disorders. The proposed research seeks to evaluate the efficacy of TBT by assessing psychiatric symptomatology and related impairment outcomes in Veterans with social anxiety disorder and comorbid posttraumatic stress via a randomized controlled trial of TBT and an existing DST. Assessments will be completed at pre-, mid-, and post-treatment, and at 6-month follow-up. Process variables also will be investigated.",[31],"2026-02-06",{"date":459,"type":37},"2026-02-10",{"date":461,"type":37},"2024-04-01",{"date":463,"type":22},"2027-10-31",{"name":465,"class":466},"VA Office of Research and Development","FED",{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":473,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":315,"enrollmentInfo":475,"targetDuration":4,"studyType":23,"phases":477,"briefSummary":478,"conditions":479,"keywords":481,"overallStatus":486,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":70},"100624183","brief-interpretation-bias-modification-for-social-anxiety-disorder-in-pakistani-young-adults-an-experimental-evaluation-100624183","NCT07406321","Brief Interpretation Bias Modification for Social Anxiety Disorder in Pakistani Young Adults: An Experimental Evaluation","Efficacy of Cognitive Bias Modification Itervention in Young Adult With Social Anxiety","BIBM-SAD-PYA","Inclusion Criteria:\n\n* age 18 to 25 years\n* Social Phobia Inventory score greater than 19\n* at least moderate severity on the DSM-5-TR Severity Measure for Social Anxiety Disorder-Adult\n* able to read study materials\n* provides written informed consent.\n\nExclusion Criteria:\n\n* clinically elevated depressive symptoms on Beck Depression Inventory-II at or above prespecified cutoff \\[above 16\\]\n* clinically elevated general anxiety symptoms on the Beck Anxiety Inventory at or above prespecified cutoff \\[ above 20\\]\n* current medical or psychiatric condition likely to interfere with safe or valid participation\n* prior participation in this trial.",{"count":476,"type":22},130,[25],"This randomized, single-blind trial tests whether one session of interpretation bias modification reduces immediate social-evaluative anxiety and shifts interpretation bias in Pakistani university students aged 18 to 25 years with elevated social anxiety. Participants are assigned to either feedback-contingent interpretation bias modification or a structurally matched interpretation control condition. Primary and secondary outcomes are assessed before and after the intervention session using short-form state-trait anxiety measures and Word-Sentence Association Paradigm endorsement indices.",[31,480],"Interpretation Bias",[482,483,31,484,485],"interpretation bias modification","Word-Sentence Association Paradigm","Pakistan Young Adult","Cogntive Bias Modification","NOT_YET_RECRUITING","2026-02-05",{"date":489,"type":37},"2026-02-12",{"date":491,"type":22},"2026-02",{"date":493,"type":22},"2026-04",{"name":495,"class":44},"Ather Mujitaba",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":503,"targetDuration":4,"studyType":23,"phases":504,"briefSummary":506,"conditions":507,"keywords":508,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":525,"completionDateStruct":526,"leadSponsor":527,"locationsCount":529},"100578275","phase-2-a-clinical-trial-to-assess-the-efficacy-safety-and-tolerability-of-a-repeat-dose-of-fasedienol-nasal-spray-for-the-acute-treatment-of-anxiety-in-adults-with-social-anxiety-disorder-100578275","NCT06809179","A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder","A Phase 2, Three-arm, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol (PH94B) Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder, With an Open-Label Extension","Inclusion Criteria:\n\n* Written informed consent provided prior to conducting any study-specific assessment.\n* Male and female adults, 18 through 65 years of age, inclusive.\n* Current diagnosis of SAD as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, and confirmed by the Mini-International Neuropsychiatric Interview (MINI).\n* Clinician-rated Liebowitz Social Anxiety Score (LSAS) total score ≥70 at Screening (Visit 1).\n* Clinician-rated Hamilton Depression Rating Scale (HAM-D) (17-items) total score \\\u003C16.\n* Female subjects of childbearing potential must be able to commit to the consistent and correct use of an effective method of birth control throughout the study\n* Subjects must have normal olfactory function\n\nExclusion Criteria:\n\n* Any history of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, psychosis, anorexia or bulimia, premenstrual dysphoric disorder, autism spectrum disorder, or obsessive-compulsive disorder.\n* Any other current principal or personality disorder (previously known as Axis I or Axis II disorders), except for specific phobias or generalized anxiety disorder, provided that these are not the primary diagnosis.\n* Subjects who meet criteria for moderate or severe alcohol use disorder within the 1 year prior to study entry, or any use of illicit substances or tetrahydrocannabinol (\"THC\") within 2 months prior to study entry.\n* In the opinion of the investigator, the subject has a significant risk for suicidal behavior during the course of their participation in the study, or the subject is considered to be an imminent danger to themself or others.\n* Clinically significant nasal pathology or history of significant nasal trauma, nasal surgery, total anosmia, or nasal septum perforation that may have damaged the nasal chemosensory epithelium.\n* Two or more documented failed adequate treatment trials with a registered medication approved for SAD.\n* Currently receiving cognitive-behavioral therapy (CBT), exposure therapy, or acceptance and commitment therapy.\n* Subjects taking psychotropic medications within 30 days before Visit 2.\n* Use of any over-the-counter product, prescription product, off-label treatment, cannabidiol (\"CBD\"), or herbal preparation for treatment of the symptoms of anxiety or social anxiety within 30 days before Visit 2.\n* Prior participation in a clinical trial involving fasedienol.\n* Participation in any other clinical trial within the last 30 days or during the course of the current trial.\n* Subjects with a positive urine drug screen.\n* Women who have a positive urine pregnancy test.\n* Women who are currently breastfeeding are not eligible unless they are willing to stop breastfeeding for the duration of the study.\n* Subjects who have tested positive and\u002For have exhibited symptoms consistent with SARS-CoV-2 infection during the 4 weeks prior to Screening (Visit 1).\n* Any clinically significant medical history or findings as determined by the Investigator that could interfere with the objectives of the study or put the participant at risk.",{"count":282,"type":22},[505],"PHASE2","This U.S. multicenter, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the efficacy, safety, and tolerability of a repeat intranasal (i.n.) dose of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months, will be assessed in those subjects who complete PH94B-CL036 and choose to enter the distinct open-label extension phase of the study.",[31],[509,510,131,299,413,511,512,513,514,515,516,517,178,518,519,520,521,522],"Fasedienol","PH94B","pherine","pherine nasal spray","acute treatment","anxiolytic","mental health","performance anxiety","anxiety nasal spray","public speaking anxiety","social phobia","phobic disorders","mental disorder","speech task","2026-02-03",{"date":487,"type":37},{"date":65,"type":37},{"date":91,"type":22},{"name":528,"class":248},"VistaGen Therapeutics, Inc.",9,{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":4,"overallStatus":486,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":546,"leadSponsor":547,"locationsCount":4},"100622338","metacognitive-therapy-compared-to-cognitive-behavioral-therapy-100622338","NCT07382323","Metacognitive Therapy Compared to Cognitive-behavioral Therapy","Transdiagnostic Metacognitive Therapy Compared to Disorder-specific Cognitive-behavioral Therapy for Anxiety Disorders: a Qualitative Study","Inclusion Criteria:\n\n* Age 18 years or older,\n* A principal diagnosis of generalized anxiety disorder, social anxiety disorder, or posttraumatic stress disorder,\n* No change in dose during the last six weeks if on pharmacological treatment, and\n* Ability to read and speak Swedish.\n\nExclusion Criteria:\n\n* A current diagnosis of psychotic disorder, bipolar disorder, neurocognitive disorder, or moderate to severe substance use disorder,\n* Acute suicide risk, or\n* Concurrent psychological treatment.",{"count":198,"type":22},[25],"This is a qualitative study of participants who have taken part in a randomized controlled trial comparing transdiagnostic metacognitive therapy and disorder-specific cognitive-behavioral therapy for anxiety disorders. The purpose of the study is to explore participant perceptions of the respective treatment models to facilitate implementation and dissemination of the treatments.",[30,31,541],"Posttraumatic Stress Disorder (PTSD)","2026-02-02",{"date":544,"type":37},"2026-02-04",{"date":491,"type":22},{"date":91,"type":22},{"name":548,"class":44},"Karolinska Institutet",{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":123,"sex":17,"minAge":555,"maxAge":556,"enrollmentInfo":557,"targetDuration":4,"studyType":23,"phases":558,"briefSummary":559,"conditions":560,"keywords":561,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":70},"100556527","very-brief-exposure-development-of-a-novel-exposure-modality-for-social-anxiety-disorder-in-transition-age-youth-100556527","NCT06526260","Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth","Inclusion Criteria:\n\n* Patient Population\n\n  * Males and females aged 16-22. This age range corresponds with our prior studies of very brief exposure (VBE) in Specific Phobia and will include older adolescents while minimizing potential developmental effects on circuit activation.\n  * Youth with a Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of Social Anxiety Disorder (SAD) on Kiddie Schedule for Affective Disorders and Schizophrenia for School-Aged Children, Computerized version (K-SADS-COMP) for youth ages 16-17, or the computerized version of Structured Clinical Interview for the DSM-5 (NetSCID) for youth ages 18+.\n* Healthy Population\n\n  • Male and female youth aged 16-22.\n* Parents • Parent\u002Fcaregiver of all ages, no restrictions who are fluent in either English or Spanish.\n\nExclusion Criteria:\n\n* Patient Population\n\n  * Primary language other than English or Spanish.\n  * Active suicidality on the Colombia-Suicide Severity Scale (plan, intent, or behavior)\n  * Ferromagnetic implants (e.g., pacemaker), metal braces, retainers, tattoos or permanent make-up with metallic content, transdermal medicinal patches that cannot be removed.\n  * Current psychoactive medication.\n  * Lifetime diagnosis of: obsessive-compulsive disorder (OCD), psychotic, bipolar, autism spectrum disorder, intellectual disability on the KSADS-COMP or NetSCID.\n  * Any serious neurological or medical conditions (e.g., Lupus, cancer, human immunodeficiency virus positive (HIV+)) as reported by potential participants.\n  * Current Post-Traumatic Stress Disorder (PTSD) diagnosis.\n  * Current severe substance abuse (except tobacco\u002Fnicotine).\n  * Pregnancy, as determined by the participant's self-report prior to the magnetic resonance imaging (MRI) scan.\n* Healthy Population\n\n  * Primary language other than English or Spanish.\n  * Lifetime disorders: any anxiety disorders, OCD, psychotic, bipolar, autism spectrum disorder, intellectual disability; any psychiatric disorder in the past 2 years\n  * Current depression disorder.\n  * Active psychiatric disorder in the past 2 years.\n  * Serious neurological or medical conditions.\n  * Current psychoactive medication.\n  * Ferromagnetic implants (e.g., pacemaker), metal braces, retainers, tattoos or permanent make-up with metallic content, transdermal medicinal patches that cannot be removed.\n  * Active suicidality on the Colombia-Suicide Severity Scale (plan, intent, or behavior).\n  * Pregnancy, as determined by the participant's self-report prior to the MRI scan.\n* Parents • Primary language other than English or Spanish.","16 Years","22 Years",{"count":103,"type":22},[25],"The goal of this clinical trial is to identify the circuit activations by very brief exposure (VBE) among youth with social anxiety disorder (SAD) in order to develop a novel intervention for those with SAD. The secondary objectives of this study are to measure the effect of VBE on subjective fear ratings, and participants' awareness and tolerance of the exposure stimuli.\n\n* The primary outcome of this study is the mean activation of frontostriatal and prefrontal brain regions to facial stimuli, as measured by Blood Oxygen Level Dependent (BOLD) response, in 4 regions of interest during the magnetic resonance imaging (MRI).\n* Another primary outcome of the study is to identify networks of regions subserving emotion regulation and attention, as measured by BOLD response of corresponding brain regions.\n\nSecondary Outcomes\n\n-The secondary outcome of this study is the fear induced by exposure to facial expression stimuli as measured by a 4-point fear scale during the functional magnetic resonance imaging (fMRI) after each block of 10 facial expression stimuli trials.\n\nParticipants will participate in an interview where they will answer questions both inside and outside of the MRI scan. Participants will be asked to rate on a scale the imagines they see while undergoing MRI scan.",[31],[562,563],"Youth","Very Brief Exposure","2025-12-11",{"date":566,"type":37},"2025-12-16",{"date":568,"type":37},"2024-08-14",{"date":570,"type":22},"2026-07",{"name":572,"class":44},"Children's Hospital Los Angeles",{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":577,"acronym":4,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":579,"targetDuration":4,"studyType":23,"phases":581,"briefSummary":582,"conditions":583,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":70},"100448269","validating-an-autonomous-interactive-internet-based-delivery-of-an-empirically-supported-cognitive-behavioral-therapy-for-comorbidity-100448269","NCT05117255","Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity","Inclusion Criteria:\n\n* current (past 30 days) Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of panic disorder with or without agoraphobia (PD\u002FAg), generalized anxiety disorder (GAD) or social anxiety disorder (SAD)\n* receiving treatment primarily for alcohol (vs. drug) dependence\n* ability to provide informed consent\n* a minimum of an eighth grade English reading level\n* status as a residential patient in the Lodging Plus (LP) addiction treatment program\n* sufficient time left in their residential LP care to complete the study protocol through the post-treatment assessment\n\nExclusion Criteria:\n\n* cognitive or medical impairments that prohibit study participation as determined by study PI\n* serious suicide risk determined by study PI\n* court-ordered treatment. (The exclusion is based on its classification as a \"vulnerable\" population.)\n* Self-reported past participation in a Kushner intervention study while in Lodging Plus",{"count":580,"type":22},256,[25],"This project is designed to determine if a computer-delivered cognitive-behavioral treatment can improve the otherwise poor alcohol use disorder treatment outcomes for individuals with a co-occurring anxiety disorder. In the past, the investigators showed that this treatment does improve outcomes for these individuals when delivered by a therapist. If the present work shows that the computer-delivered version is also effective, it would provide an inexpensive program with virtually unlimited scalability to enable access to the treatment by many more individuals than is currently the case.",[30,32,31,584,585],"Alcohol Use Disorder","Depression","2025-12-09",{"date":588,"type":37},"2025-12-17",{"date":590,"type":37},"2022-01-04",{"date":592,"type":22},"2027-03-01",{"name":594,"class":44},"University of Minnesota",{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":17,"minAge":601,"maxAge":339,"enrollmentInfo":602,"targetDuration":4,"studyType":23,"phases":604,"briefSummary":606,"conditions":607,"keywords":608,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":617,"locationsCount":70},"100607731","phase-4-comparison-of-the-effectiveness-level-of-virtual-reality-exposure-therapy-with-sertraline-treatment-in-social-anxiety-disorder-100607731","NCT07192367","Comparison of the Effectiveness Level of Virtual Reality Exposure Therapy With Sertraline Treatment in Social Anxiety Disorder","Inclusion Criteria:\n\n* RESEARCH ARM:\n\n  1. Applied to Kocaeli University Child and Adolescent Psychiatry Outpatient Clinic\n  2. Have normal intelligence based on clinical observation\n  3. Be between 12 and 17 years of age\n  4. Have a diagnosis of SAD\n  5. Have refused medication recommended for SAD\n  6. For SAD; are not currently receiving medical treatment\n  7. Have received written consent to participate in the study from them and\u002For their first-degree relatives authorized to make decisions about them\n  8. Have volunteered to participate in the study through an invitation poster presentation\n\nCONTROL ARM:\n\n1 Applied to Kocaeli University Child and Adolescent Psychiatry Outpatient Clinic 2. Have normal intelligence based on clinical observation 3. Be between 12 and 17 years of age 4. Have a diagnosis of SAD 5. Have refused medication recommended for SAD 6. For SAD; are not currently receiving medical treatment 7. Have obtained written informed consent to participate in the study from them and\u002For their first-degree relatives authorized to make decisions about them 8. Have volunteered to participate in the study through an invitation poster presentation\n\nCONTROL ARM:\n\n1 Applied to Kocaeli University Child and Adolescent Psychiatry Outpatient Clinic 2. Have normal intelligence based on clinical observation 3. Be between 12 and 17 years of age 4. Have a diagnosis of SAD 5. For SAD; Not currently receiving medical treatment 6. Volunteer 7. Written consent for participation in the study must be obtained from the patient and\u002For their first-degree relative authorized to make decisions about them.\n\n8\\. Accept sertraline treatment, routinely used in outpatient clinic follow-ups for SAD, and volunteer for the study.\n\nExclusion Criteria:\n\nRESEARCH ARM:\n\n1. Substance use disorder\n2. Schizophrenia and bipolar disorder\n3. Autism spectrum disorder\n4. Cognitive disability\n5. Neurological disorder\n6. Balance disorder\n7. Patients who have received SSRI treatment for SAD in the last 6 months\n\nCONTROL ARM:\n\n1. Substance use disorder\n2. Schizophrenia and bipolar disorder\n3. Autism spectrum disorder\n4. Cognitive disability\n5. Patients who have received SSRI treatment for SAD within the last 6 months -","12 Years",{"count":603,"type":22},56,[605],"PHASE4","This study compares two treatment approaches for adolescents and young adults with social anxiety. One group will participate in therapy sessions using a virtual reality headset, while the other group will receive sertraline, a commonly used medication for social anxiety. The goal is to see which treatment is more effective in reducing anxiety symptoms and improving daily functioning. The study will also look at how acceptable and safe these treatments are. A total of 56 participants will be enrolled at Kocaeli University, Department of Child and Adolescent Psychiatry.",[31],[407,609,610,378,260],"Virtual Reality Exposure Therapy","Sertraline","2025-09-17",{"date":613,"type":37},"2025-09-25",{"date":615,"type":37},"2024-11-15",{"date":91,"type":22},{"name":618,"class":44},"Emine Kanmaz",{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":625,"eligibilityCriteria":626,"healthyVolunteers":123,"sex":17,"minAge":18,"maxAge":627,"enrollmentInfo":628,"targetDuration":4,"studyType":23,"phases":630,"briefSummary":631,"conditions":632,"keywords":634,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":70},"100555623","differential-effects-of-in-vivo-and-virtual-exposure-therapy-in-agoraphobia-100555623","NCT06514495","Differential Effects of in Vivo and Virtual Exposure Therapy in Agoraphobia","Differential Effects of in Vivo and Virtual Exposure Therapy on the Interoception and Reactivity of Different Body Systems in Agoraphobia","VRExpo","Inclusion Criteria:\n\n* Experimental group: Diagnosis of agoraphobia with or without panic disorder\n* Clinical control group: diagnosis of social phobia\n* Control group: healthy individuals without acute or chronic mental illness\n* A depressive disorder may be present as a comorbid diagnosis in the experimental group and the clinical control group\n\nExclusion Criteria:\n\n* Other mental illnesses: Substance dependence, schizophrenia, bipolar disorder, dementia, eating disorders, PTSD, major depressive episode, personality disorder\n* Somatic diseases: Cancer, cardiovascular diseases, epilepsy, autoimmune diseases, metabolic or endocrine diseases\n* Taking psychotropic medication (except antidepressants) or medication that affects the cardiovascular system (e.g. beta-blockers), medication containing cortisone, use of creams with corticosteroids\n* Pregnancy, breastfeeding\n* Ongoing psychotherapy","75 Years",{"count":629,"type":22},68,[25],"Anxiety disorders, including agoraphobia, are prevalent in the German population, leading affected individuals to avoid specific places like crowds or public transport. Although cognitive-behavioral therapy with exposure is an effective treatment, many patients resort to medication rather than therapy. Virtual Reality Exposure Therapy (VRET) shows promise in easing exposure treatment with customizable scenarios. Interoception (body symptom perception) and the endocannabinoid system are explored as factors in maintaining agoraphobia. Studies investigate how therapies like exposure (both in vivo and in VR) impact these factors and treatment outcomes. Interoception, especially in panic disorder patients, plays a crucial role, with accurate heartbeat perception linked to maintaining anxiety. The endocannabinoid system, affecting various functions, is studied for its role in therapy outcomes and its modulation of the body's stress response. The study aims to understand how these systems interact in agoraphobic patients and how therapy affects their functionality.",[633,31],"Agoraphobia; Panic",[635,636,637,638,639,640],"exposure","virtual reality","interoception","cortisol","immune system","endocannabinoids","2025-08-26",{"date":643,"type":37},"2025-09-03",{"date":645,"type":37},"2025-05-01",{"date":647,"type":22},"2027-08-01",{"name":649,"class":44},"Johannes Gutenberg University Mainz",{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":4,"eligibilityCriteria":656,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":657,"targetDuration":4,"studyType":23,"phases":659,"briefSummary":660,"conditions":661,"keywords":667,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":675,"completionDateStruct":677,"leadSponsor":679,"locationsCount":70},"100472117","respiratory-training-in-the-treatment-of-transdiagnostic-pathological-anxiety-100472117","NCT05427708","Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety","Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Clinically elevated anxiety as indicated by an eight or higher on the Overall Anxiety Severity and Impairment Scale (OASIS).\n2. Meets DSM-5 criteria for one or more of the following anxiety or trauma-related disorders as their \"primary\" mental disorder:\n\n   * Generalized Anxiety Disorder\n   * Panic Disorder\n   * Health Anxiety\n   * Agoraphobia\n   * Social Anxiety Disorder\n   * Posttraumatic Stress Disorder\n   * Acute Stress Disorder\n   * Adjustment Disorder with primary anxious mood\n   * Anxiety disorder not otherwise specified\n3. No current use of psychotropic medications or stable on current medications for at least 6 weeks\n4. Age 18+.\n5. Able to arrange transportation to our laboratory for study appointments.\n6. Fluent in English.\n\nExclusion Criteria:\n\n1. No history of medical conditions that would contraindicate participation in fear-provocation or respiratory challenges, including:\n\n   * Cardiovascular or respiratory disorders\n   * High blood pressure\n   * Epilepsy\n   * Strokes\n   * Seizures\n   * History of fainting\n   * Pregnant or lactating\n2. Not currently receiving other psychological treatment for anxiety.\n3. No history of a suicide attempt within the past 6 months.\n4. No history of psychosis within the past 6 months.\n5. No history of moderate to severe alcohol or substance use disorder (with the exception of nicotine) within the past 3 months.\n6. Does not endorse COVID-19 symptoms during the screening phase.",{"count":658,"type":22},180,[25],"Purpose of the Research: The primary aim of the proposed study is to conduct a randomized parallel-group 2-arm clinical trial investigating capnometry-guided respiratory intervention (CGRI) for pathological anxiety. CGRI aims to raise end-tidal CO2 levels thereby lowering hyperventilation-induced respiratory alkalosis and its associated fear-eliciting somatic reactions. Psycho-education about anxiety and its effects (PsyEd) will serve as a credible control comparator.",[260,662,30,32,170,663,31,664,665,666],"Trauma","Illness Anxiety Disorder","Posttraumatic Stress Disorder","Acute Stress Disorder","Adjustment Disorder With Anxious Mood",[668,669,670,671],"Psychoeducation","Respiratory training","Transdiagnostic","Intervention","2025-08-18",{"date":674,"type":37},"2025-08-24",{"date":676,"type":37},"2022-08-22",{"date":678,"type":22},"2027-05",{"name":680,"class":44},"University of Texas at Austin",{"id":682,"slug":683,"hasResults":12,"nctId":684,"briefTitle":685,"officialTitle":686,"acronym":4,"eligibilityCriteria":687,"healthyVolunteers":12,"sex":17,"minAge":601,"maxAge":18,"enrollmentInfo":688,"targetDuration":690,"studyType":232,"phases":4,"briefSummary":691,"conditions":692,"keywords":4,"overallStatus":486,"whyStopped":4,"lastUpdateSubmitDate":694,"lastUpdatePostDateStruct":695,"startDateStruct":697,"completionDateStruct":698,"leadSponsor":700,"locationsCount":4},"100602494","the-impact-of-social-anxiety-on-adolescents-diagnosed-with-primary-headache-a-case-control-study-100602494","NCT07124234","The Impact of Social Anxiety on Adolescents Diagnosed With Primary Headache: A Case-control Study","Assessment of the Impact of Social Anxiety on Primary Headache in Adolescents: A Case-Control Study","Inclusion Criteria:\n\n* Adolescents aged 12-18 years\n* Case group: Participants who will be diagnosed with primary headache according to InternationalClassification of Headache Disorders, 3rd edition (ICHD-3) criteria, confirmed by a pediatric neurologist\n* Control group: Participants who will have no history of recurrent headache or chronic physical\u002Fpsychiatricillness\n\nExclusion Criteria:\n\n* History of neurological disease other than primary headache\n* Any previously diagnosed psychiatric disorders\n* Regular use of psychotropic medications\n* Cognitive or developmental disabilities that would interfere with assessments",{"count":689,"type":22},200,"1 Day","This case-control study will examine whether adolescents aged 12-18 years with a diagnosis of primary headache are more likely to experience elevated social anxiety compared to matched healthy controls. Social anxiety will be assessed using the SAS-A, and the study will also explore whether environmental and sociodemographic factors such as tobacco smoke exposure, BMI, and parental education influence this relationship.",[693,31],"Primary Headache","2025-08-08",{"date":696,"type":37},"2025-08-15",{"date":696,"type":22},{"date":699,"type":22},"2025-10-15",{"name":701,"class":44},"Konya Necmettin Erbakan Üniversitesi"]